Compare ERII & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | ARVN |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.9M | 781.0M |
| IPO Year | 2008 | 2018 |
| Metric | ERII | ARVN |
|---|---|---|
| Price | $10.68 | $10.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $17.07 | $15.35 |
| AVG Volume (30 Days) | 715.6K | ★ 838.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.00 | ★ 58.84 |
| EPS | ★ 0.42 | N/A |
| Revenue | $134,987,000.00 | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | $26.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $5.90 |
| 52 Week High | $18.31 | $14.22 |
| Indicator | ERII | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 44.81 |
| Support Level | $9.47 | $9.02 |
| Resistance Level | $14.78 | $12.43 |
| Average True Range (ATR) | 0.33 | 0.64 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 51.13 | 44.71 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.